Des arg9 leu8 bradykinin dalbk

Icatibant (peptide kinin B₂ receptor antagonist) and des-Arg⁹-[Leu⁸]-bradykinin (DALBk; peptide kinin B₁ receptor antagonist) were obtained from Sigma Chemical Company (St. Louis, MO, USA). FR173657 (non-peptide kinin B₂ receptor antagonist) and SSR240612 (non-peptide kinin B₁ receptor antagonist) were obtained from Sanofi-Aventis (Germany). Aprotinin was acquired from Sigma-Aldrich Chemical Company (St. Louis, MO, USA). Kinin receptor antagonists and Aprotinin were prepared in a saline solution (0.9% NaCl), which was used as the vehicle in control groups. The enzyme immunoassay kit for bradykinin was obtained from Peninsula Laboratories International, Inc. (San Carlos, CA, USA). The doses of the drugs used in this study were based on pilot experiments or previous studies. They were administered in a volume of 10 mL/kg (systemic administration) or 20 μL/paw (intraplantar injection) [22 (link),23 (link)].

Anastrozole and letrozole were purchased from Tocris Bioscience (Bristol, UK) and were diluted in 0.5% carboxymethylcellulose and 99.5% of NaCl (0.9%). Paclitaxel (6 mg/mL of Paclitaxel in Cremophor EL and dehydrated ethanol) was purchased from Glenmark (Buenos Aires, ARG) and was dissolved in NaCl (0.9%). Icatibant (kinin B₂ receptor peptide antagonist), des-Arg⁹-[Leu⁸]-bradykinin (DALBk; kinin B₁ receptor peptide antagonist) were purchased from Sigma-Aldrich Chemical Company (St. Louis MO, USA) and were also prepared in NaCl (0.9%). The enzyme immunoassay kit for bradykinin was obtained from Phoenix Pharmaceuticals, Inc. (California, USA). Specific anti-B₁ (bs-8675R–lot 9C20V14) or anti-B₂ (bs-2422R–lot AG08307921) antibodies were acquired from Bioss Antibodies (Massachusetts, USA) and secondary antibody (sc-2357–lot L1218) was obtained from Santa Cruz Biotechnology (California, USA). Paclitaxel from semisynthetic ≥ 97% (in vitro assays) was acquired from Sigma-Aldrich Chemical Company (St. Louis MO, USA). Annexin-V and 3- (4, 5-dimethyl-2-thiazolyl) -2, 5-diphenyl-2H-tetrazolium bromide] salt (MTT; 5 mg/mL solution) were obtained from Life Technologies (São Paulo, BR). The 7-Amino-Actinomycin D (7AAD) was acquired from BD Biosciences (California, USA). The doses of the drugs used in this study were based on previous studies^{13 (link),15 (link),23 (link),40 (link),72 (link)}.